At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On January 24, Alvotech and Bioventure, a subsidiary of GlobalOne Healthcare Holding LLC, announced that the Saudi Food & Drug Authority has approved SIMLANDI...
Saudi ArabiaFood, Drugs, Healthcare, Life Sciences
On January 24, Alvotech and Bioventure, a subsidiary of
GlobalOne Healthcare Holding LLC,
announced that the Saudi Food & Drug Authority has approved
SIMLANDI, a biosimilar referencing HUMIRA (adalimumab), in Saudi
Arabia. According to the press release, Bioventure is
Alvotech's exclusive strategic partner for the
commercialization of SIMLANDI in the Middle East and North Africa
and will be responsible for commercialization of the biosimilar. As
we've previously reported, the same biosimilar has been
approved in Canada as
SIMLANDI; in the EU, Norway, Iceland, Lichtenstein, the UK,
Switzerland as
HUKYNDRA; and in Australia as
CIPTUNEC/ARDALICIP.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
